Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels
- PMID:20683399
- DOI: 10.1111/IGC.0b013e3181e82a7f
Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels
Abstract
Objectives: This study was conducted to estimate the accuracy of [18F]-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) as compared with contrast-enhanced CT (CECT) in detecting cancer in patients who have normal cancer antigen (CA)-125 (<35 U/dL) but are suspected of having a recurrent disease based on clinical symptoms.
Methods: We retrospectively reviewed the records of patients who had undergone primary cytoreductive surgery and subsequently underwent CECT and FDG-PET/CT for suspected recurrence. [18F]-fluorodeoxyglucose positron emission tomography/computed tomography and CECT interpretation to evaluate a recurrent disease was carried out independently by 2 experienced radiologists who were blinded to the final diagnosis for the suspected recurrence. Long-term follow-up imaging (12 months) and biopsy reports were used to assess the true status of the suspected recurrence seen on FDG-PET/CT or CECT. Sensitivity and specificity of all modalities were estimated. McNemar test was used to compare pairs of modalities. All tests were 2-sided, and P < or = 0.05 was considered statistically significant.
Results: Sixty-six patients met the eligibility criteria for inclusion in our analysis. Fifty-eight percent (18/31) and 54% (17/31) of the patients with normal CA-125 levels had evidence of a recurrent disease on FDG-PET/CT and CECT, respectively. Thirty-one percent (6/19) of the patients with no indication of cancer on CECT had evidence of disease on FDG-PET/CT images, which was supported by pathological proof.
Conclusion: [18F]-Fluorodeoxyglucose positron emission tomography/computed tomography is capable of detecting ovarian cancer recurrence in symptomatic patients with normal CA-125 levels and, in this setting, has slightly better sensitivity than CECT and can be considered as the frontline modality for all such patients.
Similar articles
- The role of FDG-PET/CT in ovarian cancer patients with high tumor markers or suspicious lesion on contrast-enhanced CT in evaluation of recurrence and/or in determination of intraabdominal metastases.Sari O, Kaya B, Kara PO, Gedik GK, Celik C, Ozbek O, Serdengecti M.Sari O, et al.Rev Esp Med Nucl Imagen Mol. 2012 Jan-Feb;31(1):3-8. doi: 10.1016/j.remn.2011.03.008. Epub 2011 May 6.Rev Esp Med Nucl Imagen Mol. 2012.PMID:21549452
- Utility of (18) F-FDG PET/CT and CECT in conjunction with serum CA 19-9 for detecting recurrent pancreatic adenocarcinoma.Rayamajhi S, Balachandran A, Katz M, Reddy A, Rohren E, Bhosale P.Rayamajhi S, et al.Abdom Radiol (NY). 2018 Feb;43(2):505-513. doi: 10.1007/s00261-017-1316-z.Abdom Radiol (NY). 2018.PMID:28900703
- Role of 18F-FDG PET/CT in diagnosing peritoneal carcinomatosis in the restaging of patient with ovarian cancer as compared to contrast enhanced CT and tumor marker Ca-125.Rubini G, Altini C, Notaristefano A, Merenda N, Rubini D, Ianora AA, Asabella AN.Rubini G, et al.Rev Esp Med Nucl Imagen Mol. 2014 Jan-Feb;33(1):22-7. doi: 10.1016/j.remn.2013.06.008. Epub 2013 Aug 13.Rev Esp Med Nucl Imagen Mol. 2014.PMID:23948509
- [F-18-FDG positron emission tomography in the diagnosis of ovarian recurrence. Comparison with CT scan and CA 125].García Velloso MJ, Boán García JF, Villar Luque LM, Aramendía Beitia JM, López García G, Richter Echeverría JA.García Velloso MJ, et al.Rev Esp Med Nucl. 2003 Jul-Aug;22(4):217-23. doi: 10.1016/s0212-6982(03)72189-2.Rev Esp Med Nucl. 2003.PMID:12846945Review.Spanish.
- Diagnostic Performance of ¹⁸F-FDG PET and PET/CT for the Detection of Recurrent Esophageal Cancer After Treatment with Curative Intent: A Systematic Review and Meta-Analysis.Goense L, van Rossum PS, Reitsma JB, Lam MG, Meijer GJ, van Vulpen M, Ruurda JP, van Hillegersberg R.Goense L, et al.J Nucl Med. 2015 Jul;56(7):995-1002. doi: 10.2967/jnumed.115.155580. Epub 2015 May 7.J Nucl Med. 2015.PMID:25952733Review.
Cited by
- Role of Positron Emission Tomography/Computed Tomography in Epithelial Ovarian Cancer.Chandra R, Kumari S, Bhatla N, Kumar R, Tiwari A, Sachani H, Kumar L.Chandra R, et al.Indian J Nucl Med. 2023 Oct-Dec;38(4):366-375. doi: 10.4103/ijnm.ijnm_42_22. Epub 2023 Dec 20.Indian J Nucl Med. 2023.PMID:38390547Free PMC article.Review.
- The ability of whole-body SUVmax in F-18 FDG PET/CT to predict suboptimal cytoreduction during primary debulking surgery for advanced ovarian cancer.Chong GO, Jeong SY, Lee YH, Lee HJ, Lee SW, Han HS, Hong DG, Lee YS.Chong GO, et al.J Ovarian Res. 2019 Feb 4;12(1):12. doi: 10.1186/s13048-019-0488-2.J Ovarian Res. 2019.PMID:30717813Free PMC article.
- Diagnostic and prognostic evaluation of fluorodeoxyglucose positron emission tomography/computed tomography and its correlation with serum cancer antigen-125 (CA125) in a large cohort of ovarian cancer patients.Evangelista L, Palma MD, Gregianin M, Nardin M, Roma A, Nicoletto MO, Nardelli GB, Zagonel V.Evangelista L, et al.J Turk Ger Gynecol Assoc. 2015 Aug 6;16(3):137-44. doi: 10.5152/jtgga.2015.15251. eCollection 2015.J Turk Ger Gynecol Assoc. 2015.PMID:26401105Free PMC article.
- To Enhance or Not to Enhance? The Role of Contrast Medium18F-FDG PET/CT in Recurrent Ovarian Carcinomas.Massollo M, Fiz F, Bottoni G, Ugolini M, Paparo F, Puppo C, Provinciali N, Iacozzi M, Altrinetti V, Cistaro A, Cabria M, DeCensi A, Treglia G, Piccardo A.Massollo M, et al.Medicina (Kaunas). 2021 Jun 1;57(6):561. doi: 10.3390/medicina57060561.Medicina (Kaunas). 2021.PMID:34206116Free PMC article.
- Diagnostic value of integrated ¹⁸F-fluoro-2-deoxyglucose positron emission tomography/computed tomography in recurrent epithelial ovarian cancer: accuracy of patient selection for secondary cytoreduction in 134 patients.Lee YJ, Kim YM, Jung PS, Lee JJ, Kim JK, Kim YT, Nam JH.Lee YJ, et al.J Gynecol Oncol. 2018 May;29(3):e36. doi: 10.3802/jgo.2018.29.e36. Epub 2018 Feb 1.J Gynecol Oncol. 2018.PMID:29400023Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous